A A A text size:
Polski

Quick links  

Menu

Main page › Business partners section › In-licensing
print

In-licensing   

We focus our interest on products that may enrich the Polpharma portfolio, especially those planned for launch by 2013:

 

CARDIOVASCULAR
  • antiarrhytmic preparations
  • antihypertensives
  • diuretics
  • cholesterol and triglyceride reduction preparations
  • vasotherapeutics
RESPIRATORY
  • drugs for obstructive airway diseases, adrenergics, inhalants
  • antihistamines
GASTRO
  • H2-receptor antagonists (antiulcer)
  • proton pump inhibitors (antiulcer)
CENTRAL NERVOUS SYSTEM
  • sedatives, hypnotics
  • antiepileptics
  • antidepressants
  • analgesics
  • nootropic agents
  • topical anaesthetics
  • antipsychotics
  • antiparkinsonian and antialzheimer agents
  • antimigraine preparations
OTC
  • analgesics, antipyretics, antiinflammatory agents
  • platelet aggregation inhibitors
  • sedatives
  • ophthalmic irrigating solutions
  • sympathomimetics, vasoconstrictors

 

We look into products that may introduce new therapeutic groups into the Polpharma portfolio:

 

  • oncology
  • antibiotics
  • ophthalmology
  • dermatology

 

Additionally

 

We are open for other types of cooperation:

  • Collaborate on modern drug forms: generics plus, OTC, mass market,
  • Start cooperation for the use of  Polpharma as facility for manufacturing finished dosage forms and APIs,
  • Obtain registration dossiers from the markets where Polpharma is present (CEE, CIS, and Russia),
  • Purchase registration dossiers with an advanced registration process.

Polpharma Group:

Strategic partner:

© POLPHARMA S.A. All rights reserved.
Realizacja: Ideo